Is retesting in growth hormone deficient children really useful?

Cristina Meazza, Chiara Gertosio, Sara Pagani, Alba Pilotta, Carmine Tinelli, Fabio Buzi, Giovanni Farello, Giulia Genoni, Gianni Bona, Mauro Bozzola

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Patients with childhood-onset GH deficiency (GHD) are usually retested after achievement of near final height, to verify whether they need to continue GH treatment. We investigated if GH stimulation test is necessary to confirm a persistent status of GHD or if other parameters could be a reliable predictor of GHD persistence. METHODS: One-hundred and sixty-four children with idiopathic GHD (55 females and 109 males) were retested when they reached near final height using GH releasing hormone (GHRH)+arginine test or arginine alone. RESULTS: At diagnosis, 23.8% of patients showed severe GHD (GH peak at diagnosis <5 ng/mL) and 76.2% showed partial GHD (GH peak <10 ng/mL). At time of retesting, 82.1% of severe GHD and 82.4% of partial GHD patients showed transient GHD. IGF-I levels were not different between persistent (0.18±1.18 SDS) and transient GHD subjects (0.17±0.82 SDS). Furthermore, among persistent severe GHD patients only two showed very reduced levels of IGF-I (<-2.0 SDS). CONCLUSIONS: The majority of patients idiopathic GHD proved to be transient. IGF-I levels alone do not discriminate subjects with persistent from those with transient GHD. Therefore, after the end of GH substitutive treatment, a reevaluation of GH secretion is mandatory to verify the persistence of GHD in adulthood.

Original languageEnglish
Pages (from-to)325-330
Number of pages6
JournalMinerva Endocrinologica
Volume42
Issue number4
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Growth Hormone
Insulin-Like Growth Factor I
Arginine
Hormones
Therapeutics

Keywords

  • Child
  • Deficiency
  • Growth hormone
  • Insulin-Like Growth Factor I
  • Therapy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Is retesting in growth hormone deficient children really useful? / Meazza, Cristina; Gertosio, Chiara; Pagani, Sara; Pilotta, Alba; Tinelli, Carmine; Buzi, Fabio; Farello, Giovanni; Genoni, Giulia; Bona, Gianni; Bozzola, Mauro.

In: Minerva Endocrinologica, Vol. 42, No. 4, 01.12.2017, p. 325-330.

Research output: Contribution to journalArticle

Meazza, C, Gertosio, C, Pagani, S, Pilotta, A, Tinelli, C, Buzi, F, Farello, G, Genoni, G, Bona, G & Bozzola, M 2017, 'Is retesting in growth hormone deficient children really useful?', Minerva Endocrinologica, vol. 42, no. 4, pp. 325-330. https://doi.org/10.23736/S0391-1977.16.02510-4
Meazza, Cristina ; Gertosio, Chiara ; Pagani, Sara ; Pilotta, Alba ; Tinelli, Carmine ; Buzi, Fabio ; Farello, Giovanni ; Genoni, Giulia ; Bona, Gianni ; Bozzola, Mauro. / Is retesting in growth hormone deficient children really useful?. In: Minerva Endocrinologica. 2017 ; Vol. 42, No. 4. pp. 325-330.
@article{2fe97b59886e4847bee4a69b2e3941fd,
title = "Is retesting in growth hormone deficient children really useful?",
abstract = "BACKGROUND: Patients with childhood-onset GH deficiency (GHD) are usually retested after achievement of near final height, to verify whether they need to continue GH treatment. We investigated if GH stimulation test is necessary to confirm a persistent status of GHD or if other parameters could be a reliable predictor of GHD persistence. METHODS: One-hundred and sixty-four children with idiopathic GHD (55 females and 109 males) were retested when they reached near final height using GH releasing hormone (GHRH)+arginine test or arginine alone. RESULTS: At diagnosis, 23.8{\%} of patients showed severe GHD (GH peak at diagnosis <5 ng/mL) and 76.2{\%} showed partial GHD (GH peak <10 ng/mL). At time of retesting, 82.1{\%} of severe GHD and 82.4{\%} of partial GHD patients showed transient GHD. IGF-I levels were not different between persistent (0.18±1.18 SDS) and transient GHD subjects (0.17±0.82 SDS). Furthermore, among persistent severe GHD patients only two showed very reduced levels of IGF-I (<-2.0 SDS). CONCLUSIONS: The majority of patients idiopathic GHD proved to be transient. IGF-I levels alone do not discriminate subjects with persistent from those with transient GHD. Therefore, after the end of GH substitutive treatment, a reevaluation of GH secretion is mandatory to verify the persistence of GHD in adulthood.",
keywords = "Child, Deficiency, Growth hormone, Insulin-Like Growth Factor I, Therapy",
author = "Cristina Meazza and Chiara Gertosio and Sara Pagani and Alba Pilotta and Carmine Tinelli and Fabio Buzi and Giovanni Farello and Giulia Genoni and Gianni Bona and Mauro Bozzola",
year = "2017",
month = "12",
day = "1",
doi = "10.23736/S0391-1977.16.02510-4",
language = "English",
volume = "42",
pages = "325--330",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Is retesting in growth hormone deficient children really useful?

AU - Meazza, Cristina

AU - Gertosio, Chiara

AU - Pagani, Sara

AU - Pilotta, Alba

AU - Tinelli, Carmine

AU - Buzi, Fabio

AU - Farello, Giovanni

AU - Genoni, Giulia

AU - Bona, Gianni

AU - Bozzola, Mauro

PY - 2017/12/1

Y1 - 2017/12/1

N2 - BACKGROUND: Patients with childhood-onset GH deficiency (GHD) are usually retested after achievement of near final height, to verify whether they need to continue GH treatment. We investigated if GH stimulation test is necessary to confirm a persistent status of GHD or if other parameters could be a reliable predictor of GHD persistence. METHODS: One-hundred and sixty-four children with idiopathic GHD (55 females and 109 males) were retested when they reached near final height using GH releasing hormone (GHRH)+arginine test or arginine alone. RESULTS: At diagnosis, 23.8% of patients showed severe GHD (GH peak at diagnosis <5 ng/mL) and 76.2% showed partial GHD (GH peak <10 ng/mL). At time of retesting, 82.1% of severe GHD and 82.4% of partial GHD patients showed transient GHD. IGF-I levels were not different between persistent (0.18±1.18 SDS) and transient GHD subjects (0.17±0.82 SDS). Furthermore, among persistent severe GHD patients only two showed very reduced levels of IGF-I (<-2.0 SDS). CONCLUSIONS: The majority of patients idiopathic GHD proved to be transient. IGF-I levels alone do not discriminate subjects with persistent from those with transient GHD. Therefore, after the end of GH substitutive treatment, a reevaluation of GH secretion is mandatory to verify the persistence of GHD in adulthood.

AB - BACKGROUND: Patients with childhood-onset GH deficiency (GHD) are usually retested after achievement of near final height, to verify whether they need to continue GH treatment. We investigated if GH stimulation test is necessary to confirm a persistent status of GHD or if other parameters could be a reliable predictor of GHD persistence. METHODS: One-hundred and sixty-four children with idiopathic GHD (55 females and 109 males) were retested when they reached near final height using GH releasing hormone (GHRH)+arginine test or arginine alone. RESULTS: At diagnosis, 23.8% of patients showed severe GHD (GH peak at diagnosis <5 ng/mL) and 76.2% showed partial GHD (GH peak <10 ng/mL). At time of retesting, 82.1% of severe GHD and 82.4% of partial GHD patients showed transient GHD. IGF-I levels were not different between persistent (0.18±1.18 SDS) and transient GHD subjects (0.17±0.82 SDS). Furthermore, among persistent severe GHD patients only two showed very reduced levels of IGF-I (<-2.0 SDS). CONCLUSIONS: The majority of patients idiopathic GHD proved to be transient. IGF-I levels alone do not discriminate subjects with persistent from those with transient GHD. Therefore, after the end of GH substitutive treatment, a reevaluation of GH secretion is mandatory to verify the persistence of GHD in adulthood.

KW - Child

KW - Deficiency

KW - Growth hormone

KW - Insulin-Like Growth Factor I

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85029721692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029721692&partnerID=8YFLogxK

U2 - 10.23736/S0391-1977.16.02510-4

DO - 10.23736/S0391-1977.16.02510-4

M3 - Article

AN - SCOPUS:85029721692

VL - 42

SP - 325

EP - 330

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 4

ER -